Cargando…

Detection of Bone Metastases by (68)Ga-DOTA-SSAs and (18)F-FDG PET/CT: A Two-Center Head-to-Head Study of Gastroenteropancreatic Neuroendocrine Neoplasms

PURPOSE: This study aimed to assess the efficacy of dual-tracer [(68)Ga-DOTA-somatostatin receptor analogs (SSAs) and (18)F-fluorodeoxyglucose (FDG)] positron emission tomography/computed tomography (PET/CT) imaging for detecting bone metastases (BMs) in patients with gastroenteropancreatic neuroend...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Rui, Xie, Qing, Yu, Fei, Du, Changzhi, Yao, Xiaochen, Zang, Shiming, Zhang, Chuan, Zhang, Pengjun, Shao, Guoqiang, Yang, Zhi, Wang, Feng, Yu, Jiangyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663244/ https://www.ncbi.nlm.nih.gov/pubmed/36447752 http://dx.doi.org/10.1155/2022/1750132

Ejemplares similares

Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Clinical and Prognostic Value of PET/CT Imaging with Combination of (68)Ga-DOTATATE and (18)F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms
por: Zhang, Panpan, et al.
Publicado: (2018)

Head-to-Head Comparison of (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study
por: Hou, Guozhu, et al.
Publicado: (2022)

Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma
por: Gu, Bingxin, et al.
Publicado: (2022)

Head-to-Head Comparison between [(68)Ga]Ga-DOTA.SA.FAPi and [(18)F]F-FDG PET/CT Imaging in Patients with Breast Cancer
por: Ballal, Sanjana, et al.
Publicado: (2023)

Dual [(68)Ga]DOTATATE and [(18)F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
por: Chan, David L., et al.
Publicado: (2022)

(68)Ga-DOTA-NT-20.3 Neurotensin Receptor 1 PET Imaging as a Surrogate for Neuroendocrine Differentiation of Prostate Cancer
por: Wu, Wenyu, et al.
Publicado: (2022)

Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG Uptake in Esophageal Cancer
por: Liu, Huipan, et al.
Publicado: (2022)

Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours
por: Kim, Yong-il, et al.
Publicado: (2020)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

Preparation and Biological Study of (68)Ga-DOTA-alendronate
por: Fakhari, Ashraf, et al.
Publicado: (2016)

Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG PET/MRI in the Preoperative Diagnosis of Gastric Cancer
por: Du, Tao, et al.
Publicado: (2023)

18F-FDG PETCT and 68Ga-DOTA PETCT mismatch with in vivo histopathological characterization of low-grade neuroendocrine pancreatic tumor
por: Queiroz, Marcello Moro, et al.
Publicado: (2021)

Initial Clinical Experience with (68)Ga-DOTA-NOC Prepared Using (68)Ga from Nanoceria-polyacrylonitrile Composite Sorbent-based (68)Ge/(68)Ga Generator and Freeze-dried DOTA-NOC Kits
por: Chandra, Piyush, et al.
Publicado: (2017)

The Diagnostic and Grading Accuracy of (68)Ga-DOTATATE and (18)F-FDG PET/MR for Pancreatic Neuroendocrine Neoplasms
por: Zhou, Jinxin, et al.
Publicado: (2022)

Adventures in radiosynthesis of clinical grade [(68)Ga]Ga-DOTA-Siglec-9
por: Käkelä, Meeri, et al.
Publicado: (2018)

[(68)Ga]Ga-DOTA-TATE uptake due to COVID-19 vaccination
por: Weiler-Sagie, Michal, et al.
Publicado: (2021)

A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer
por: Wang, Guochang, et al.
Publicado: (2023)

Is (68)Ga-DOTA-FAPI a new arrow in the quiver of dose painting in radiation dose planning in head and neck cancers?
por: Conen, Patrick, et al.
Publicado: (2020)

Physiological Biodistribution of (68)Ga-DOTA-TATE in Normal Subjects
por: Özgüven, Salih, et al.
Publicado: (2021)

Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [(68)Ga]Ga-DOTA-E-[c(RGDfK)](2) PET/CT
por: Lobeek, D., et al.
Publicado: (2020)

Safety, tolerability and clinical implementation of ‘ready-to-use’ (68)gallium-DOTA0-Tyr3-octreotide ((68)Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
por: Manoharan, Prakash, et al.
Publicado: (2020)

Head-to-head comparison of [(68)Ga]Ga-FAPI-04 and [(18)F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma
por: Kuten, Jonathan, et al.
Publicado: (2021)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

Head-to-Head Comparison of [(68) Ga]Ga-FAPI-46-PET/CT and [(18)F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer
por: Wegen, Simone, et al.
Publicado: (2022)

Application of (68)Ga-DOTA-TATE PET/CT in metastatic neuroendocrine tumor of gastrointestinal origin
por: Papadakis, Georgios Z., et al.
Publicado: (2017)

Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Mafficini, Andrea, et al.
Publicado: (2019)

An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
por: Fang, Jiayun M, et al.
Publicado: (2022)

Advances in the imaging of gastroenteropancreatic neuroendocrine neoplasms
por: Ramachandran, Anupama, et al.
Publicado: (2022)

PET-CT imaging of pulmonary inflammation using [(68)Ga]Ga-DOTA-TATE
por: Puuvuori, Emmi, et al.
Publicado: (2022)

Occupational radiation exposure assessment during the management of [(68)Ga]Ga-DOTA-TOC
por: Riveira-Martin, Mercedes, et al.
Publicado: (2022)

Standardized image quality for (68)Ga-DOTA-TATE PET/CT
por: Cox, Christina P. W., et al.
Publicado: (2020)

Head-to-head Intra-individual Comparison of [(68)Ga]-FAPI and [(18)F]-FDG PET/CT in Patients with Bladder Cancer
por: Novruzov, E., et al.
Publicado: (2022)

Role of Combined [(68)Ga]Ga-DOTA-SST Analogues and [(18)F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review
por: Carideo, Luciano, et al.
Publicado: (2019)

Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models
por: Kawasaki, Kenta, et al.
Publicado: (2018)

Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot
por: Fernandez, Cornelius J, et al.
Publicado: (2021)

Matching-adjusted indirect treatment comparison of [(177)Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [(177)Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
por: Khan, Mohid S., et al.
Publicado: (2021)

Assessment of regional pulmonary blood flow using (68)Ga-DOTA PET
por: Velasco, Carlos, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rnr7n8ufclte8ht679hcj2sa1j